ImmunoGen, Inc.
http://www.immunogen.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ImmunoGen, Inc.
Tech Transfer Roundup: Lysogene Elects Option On Gene Therapy Discovered At Weizmann Institute
French biotech brings candidate for Gaucher and Parkinson’s disease in-house under 2020 pact with Weizmann. Cellevolve, Seattle Children’s partner on cell therapies for CNS cancers.
Appetite For Korean Biotechs Turns Sour, Voronoi Withdraws IPO
Weak broader stock market sentiment, topped with negative biotech industry news, weighs on Korean bioventure IPOs in the first quarter, with unicorn Voronoi withdrawing its IPO plan. But VC financing in the sector remains steady.
Keeping Track: Novel Oncologics Submitted By Taiho, ImmunoGen, Y-mAbs; US FDA Declines Akebia’s Vadadustat
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Scrip Asks…What Does 2022 Hold For Biopharma? Part 7: People And Planet
Addressing health care inequities, providing a nurturing environment for employees and learning from the pandemic were among the aims expressed by executives surveyed by Scrip.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Site Specific
-
Drug Delivery
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule